BioNexus Gene Lab Corp

For the period ended Dec 31, 2023. Filed Apr 16, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 16, 2024

BGLC$0.82-8.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 15. Exhibits, Financial Statement Schedules

EXHIBIT INDEX

Exhibit Number	Description
1.1**	Form of Underwriting Agreement
3.1**	Articles of Incorporation of the Registrant, as currently in effect
3.2**	Bylaws of the Registrant, as currently in effect
3.3**	Certificate of Amendment filed with the Secretary of the State of Wyoming on June 7, 2017
3.4**	Certificate of Amendment filed with the Secretary of the State of Wyoming on March 29, 2023
3.5**	Certificate of Amendment filed with the Secretary of the State of Wyoming on June 5, 2023
4.1**	Registrant’s Specimen Certificate for Common Stock
4.2**	Form of Representative’s Warrant
10.1**	Share Exchange Agreement between BioNexus and Chemrex
10.2**	Employment Agreement with Yeat Min Fong
10.3**	Employment Agreement with Yee Meng Wong
10.4**	Employment Agreement with Sook Keng Yeoh
10.5**	Employment Agreement with Wei Li Leong
10.6**	Employment Agreement with Liong Tai Tan
10.7**	Director Offer Letter by and between the Registrant and Teng Fook Fong
10.8**	Director Offer Letter by and between the Registrant and Chai Ping Lin
10.9**	Director Offer Letter by and between the Registrant and Chak Hua Yew
10.10**	Director Offer Letter by and between the Registrant and Boon Teong Teoh
10.11**	Director Offer Letter by and between the Registrant and Chee Keong Yap
14.1**	Code of Business Conduct and Ethics
21.1+	List of Subsidiaries of the Registrant
31.1	Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002+
32.1	Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+
99.2**	Audit Committee Charter
99.3**	Compensation Committee Charter
99.4**	Nomination Committee Charter
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

+	Filed herewith.
**	Previously filed.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.